A Long-Term Follow-up Study to Evaluate the Durability of Virologic Response and/or Viral Resistance Patterns of Subjects With Chronic Hepatitis C Who Have Been Previously Treated with MK-5172 in a Prior Clinical Trial
Latest Information Update: 07 Jun 2022
At a glance
- Drugs Grazoprevir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme
- 09 Apr 2021 Status changed from recruiting to completed.
- 02 Feb 2021 Planned End Date changed from 24 May 2021 to 31 Mar 2021.
- 02 Feb 2021 Planned primary completion date changed from 24 May 2021 to 31 Mar 2021.